Shilpa Medicare
Shilpa Medicare's wholly-owned subsidiary Shilpa Biocare Private Limited signed an exclusive European commercialization agreement with Finland-based Orion Corporation for Shilpa's recombinant human albumin (announced Q1 FY26 / late June 2026 disclosure) — Orion gains exclusive distribution,…
- Country
- India
- Ticker
- BSE:530549
First Indian rHA Phase 1 completion Aug 2024; Orion Corporation Europe commercialization via Shilpa Biocare (Q1 FY26)
in
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant human serum albumin (rHSA) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.